Headlines,Novo Nordisk experienced a decline in stock value after recent news from its lab.,Eli Lilly, (NYSE:LLY),and Viking ...

Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...